Radiopharm Theranostics (ASX:RAD) Current Accrued Expense : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Current Accrued Expense?

Radiopharm Theranostics's Current Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Radiopharm Theranostics Current Accrued Expense Historical Data

The historical data trend for Radiopharm Theranostics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Current Accrued Expense Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Current Accrued Expense

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Current Accrued Expense	-	-	-	-	-

Radiopharm Theranostics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Radiopharm Theranostics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (ASX:RAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

RDPTF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines